You are here
Xarelto (Rivaroxaban) is an oral anticoagulant, manufactured by Johnson & Johnson and its subsidiary Janssen Pharmaceuticals in the United States. It is the first available orally active direct factor Xa inhibitor slowing down blood clot formation. The U.S. Food and Drug Administration (FDA) approved Xarelto in July 2011, and its sales have steadily grown since then.
Xarelto is prescribed to adults for either of the following reasons:
- 1. Reduce the risk of stroke and blood clots in people who have a medical condition called Atrial fibrillation.
- 2. Reduce the risk of forming a blood clot in the legs and lungs of people who have just had hip or knee replacement surgery.
- 3. Treat and reduce the recurrence of blood clots in the legs [Deep Vein Thrombosis (DVT)].
- 4. Treat and reduce the recurrence of blood clots in the lungs [Pulmonary Embolism (PE)].
Over a period of time, Xarelto has been linked to the following medical conditions
- Rectal bleeding
- Intestinal bleeding
- Brain hemorrhaging
- Death caused by uncontrolled bleeding
In 2013, the FDA issued a warning letter to the maker of Xarelto, noting that a print advertisement for the drug minimized the risks associated with it and made a misleading claim. Specifically, the FDA warned that including the risk information without any of the emphasis that was included on the benefits section made it seem as though the risks were not important. The agency noted in its letter that the most common adverse reactions with Xarelto were bleeding complications.
Uncontrollable bleeding is the most dangerous side effect for people who take Xarelto, as it has no antidote that can help to stop the bleeding.
- Indication of usage Xarelto in Medical and Pharmacy Records
- Duration of Xarelto usage
- Complications and their treatment after Xarelto intake
Medical Record Review and claim validation of Xarelto case should take approximately 4 hours in most instances; however, this approximation may vary in cases based on the volume of records.